What You Ought to Know:
– myTomorrows, a well being expertise firm that connects sufferers with all attainable pre-approval therapies, immediately introduced the shut of a $29 million financing with Avego. Avego’s progress fairness funding will gas the worldwide enlargement of myTomorrows’ built-in pharma options to make rising therapies extra equitable and accessible for sufferers globally.
– With greater than 300 million sufferers worldwide going through situations with out accepted therapy choices, and over 10,000 therapies at the moment in growth or awaiting approval – myTomorrows is addressing one in all healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval therapies, which embody medical trials and expanded entry packages (EAPs).
myTomorrows Expands World AI Platform to Speed up Affected person Entry to Pre-Approval Therapies
myTomorrows is redefining how sufferers and physicians entry investigational therapies by bridging the hole between medical growth and real-world care. The worldwide HealthTech firm operates a unified, multi-stakeholder platform that connects sufferers, physicians, trial websites, and BioPharma companions—simplifying entry to pre-approval therapies by means of the facility of AI and skilled human navigation. By bringing transparency, coordination, and perception to the therapy discovery course of, myTomorrows is accelerating international entry to modern therapies whereas advancing data-driven drug growth.
The most recent funding will gas the corporate’s worldwide enlargement and additional improve its AI-driven international platform—deepening integration with BioPharma companions to shorten medical growth timelines, enrich real-world proof technology, and strengthen regulatory perception. “This funding marks a pivotal step in our journey to provide each affected person, irrespective of the place they dwell, a good shot at tomorrow’s therapies,” mentioned Michel van Harten, CEO of myTomorrows. “Avego’s deep life sciences experience, particularly in BioPharma, shall be instrumental as we scale our platform and broaden our international affect.”
Immediately, myTomorrows operates the world’s most complete AI-powered platform for pre-approval therapies, having already supported greater than 16,900 sufferers throughout 133 nations. The platform empowers sufferers and clinicians by means of skilled steering, customized therapy matching, and seamless entry to each medical trials and expanded entry packages. For BioPharma companions, it affords end-to-end companies in trial recruitment, expanded entry administration, and real-world knowledge seize, whereas trial websites profit from unified referral methods with real-time monitoring and enhanced visibility.
By connecting each stakeholder within the therapy ecosystem, myTomorrows is laying the inspiration for a brand new period of world healthcare entry—one outlined by AI-enabled precision, adaptive regulation, and empowered sufferers. Embedded throughout well being methods worldwide, its platform supplies unbiased, actionable pathways to rising therapies, making certain that medical breakthroughs attain those that want them most—precisely when it issues.
